BioSpace News Archive

Aurealis Therapeutics and Xbiome announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer, other chronic wounds, and inflammatory disease therapy AUP-16 in Greater China.

Royal Philips, a global leader in health technology, and the University Hospital Brandenburg an der Havel have signed a 10-year strategic partnership to renew and expand the hospital’s diagnostic and therapy options through the delivery of advanced technology solutions.

BeiGene announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental new drug application for BeiGene’s BTK inhibitor BRUKINSA as a treatment for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and granted BRUKINSA breakthrough therapy designation.

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to announce that it has received a Notice of Allowance from the Canadian Patent Office for patent application No. 3101853 entitled: Compositions and Methods for Treating Idiopathic Pulmonary Fibrosis.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced it has received clearance from the U.S. Food and Drug Administration for its Omnipod® 5 Automated Insulin Delivery System for individuals aged six years and older with type 1 diabetes.

Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies.

NovaBay ® Pharmaceuticals, Inc . announces the appointments of Audrey Kunin, M.D. and Julie Garlikov to the NovaBay Board of Directors.

Amryt Announces Oleogel-S10 EMA Regulatory Update.

LAVA Therapeutics N.V., a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, announced that Stephen Hurly, president and chief executive officer, will present the latest company overview at the SVB Leerink 11th Annual Global Healthcare Conference 2022.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the voluntary withdrawal of the supplemental Biologics License Application (sBLA) for Libtayo ® (cemiplimab-rwlc) as a second-line treatment for patients with advanced cervical cancer.